{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-037257","form_type":"8-K","ticker":"DYAI","cik":"0001213809","company_name":"DYADIC INTERNATIONAL INC","filed_at":"2026-08-12T12:45:32+00:00","discovered_at":"2026-08-12T12:50:00.368214+00:00","generated_at":"2026-08-12T12:50:05.501188+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Dyadic Q2 2026 revenue flat at $961K; net loss $2.12M, cash down to $4.79M","bullets":["Revenue $961,138, down 0.6% YoY; grant revenue up $334K, R&D revenue down $89.6K.","Net loss $2,123,884 ($0.06/share) vs $1,793,774 ($0.06/share) a year ago.","Cash and investments $4.79M at June 30, down from $8.59M at Dec 31, 2025.","Commercial progress: shipments of 6 recombinant proteins, pilot sales for cultivated meat, IBT Bioservices OEM shipments, Proliant Albufree DX launch.","Transferrin productivity up ~80% at pilot scale; Gates Foundation RSV/malaria mAb programs advancing."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-037257","json":"https://secwatch.observer/filing/0001493152-26-037257.json","markdown":"https://secwatch.observer/filing/0001493152-26-037257.md","text":"https://secwatch.observer/filing/0001493152-26-037257.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213809/000149315226037257/0001493152-26-037257-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213809/000149315226037257/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T12:50:05.501188+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}